This is likely the mechanism underlying the modest efficacy of DA monotherapy in the treatment of mild acromegaly (42) as expression of DR on somatotroph adenoma may have some value in predicting clinical response to SRL (25) yet serum prolactin level does not correlate with GH responses to cabergoline (42).The very limited value of using D2R as a therapeutic marker for acromegaly is limited to identifying patients with mild disease who may respond to DA as monotherapy or as an adjunct to SRL therapy. This evidence concerns the gene DRD2 and acromegaly.